Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

During the 2022 clinical rollout of nirmatrelvir in Israel, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen in patients at highest risk for Covid-19 progression, such as those 65 years of age or older.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-09, Vol.387 (9), p.790-798
Hauptverfasser:	Arbel, Ronen, Wolff Sagy, Yael, Hoshen, Moshe, Battat, Erez, Lavie, Gil, Sergienko, Ruslan, Friger, Michael, Waxman, Jacob G., Dagan, Noa, Balicer, Ran, Ben-Shlomo, Yatir, Peretz, Alon, Yaron, Shlomit, Serby, Danielle, Hammerman, Ariel, Netzer, Doron
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antigens Antiviral Agents - therapeutic use Antiviral drugs Chronic illnesses Coronavirus Coronaviruses COVID-19 COVID-19 - virology COVID-19 Drug Treatment COVID-19 vaccines Death Disease transmission Drug dosages Hospitalization Humans Infections Infectious Disease Lactams - therapeutic use Leucine - therapeutic use Middle Aged mRNA vaccines Nitriles - therapeutic use Original Patients Performance evaluation Proline - therapeutic use Proteinase inhibitors SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sociodemographics Software Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	During the 2022 clinical rollout of nirmatrelvir in Israel, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen in patients at highest risk for Covid-19 progression, such as those 65 years of age or older.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2204919